枸地氯雷他定治疗慢性荨麻疹的效果

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (43 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨枸地氯雷他定治疗慢性荨麻疹的效果。方法选取2019 年1 月至2021 年1 月九江市第一人民医院皮肤科门诊收治的100 例慢性荨麻疹患者作为研究对象，采用随机数字表法将其分为对照组和研究组，每组各50 例。对照组患者给予氯雷他定片治疗。研究组患者给予口服枸地氯雷他定片治疗。两组患者均连续治疗28 d。比较两组患者治疗前、治疗14 d 及28 d 时的总分、瘙痒评分、风团数、风团大小、不同疗程总有效率以及转化生长因子-β1（TGF-β1）、免疫球蛋白 E（IgE）、T 细胞亚群和白介素 18（IL-18）水平。结果两组患者治疗 14、28 d 的瘙痒评分、风团数评分、风团大小评分以及总分均低于本组治疗前，差异有统计学意义（P<0.05）；研究组患者治疗14、28 d 的瘙痒评分、风团数评分、风团大小评分以及总分均低于对照组，差异有统计学意义（P<0.05）。两组患者治疗28 d 的总有效率高于治疗14 d，差异有统计学意义（P<0.05）；研究组患者治疗14、28 d 的总有效率高于对照组，差异有统计学意义（P<0.05）；两组患者治疗 14、28 d 的 TGF-β1、IgE、IL-18、CD8+均低于本组治疗前，差异有统计学意义（P<0.05）；研究组患者治疗 14、28 d 的 TGF-β1、IgE、IL-18、CD8+均低于对照组，差异有统计学意义（P<0.05）。两组患者治疗 14、28 d 的 CD4+、CD4+/CD8+水平均高于本组治疗前，差异有统计学意义（P<0.05）；研究组患者14、28 d 的CD4+、CD4+/CD8+水平均高于对照组，差异有统计学意义（P<0.05）。结论枸地氯雷他定能有效调控慢性荨麻疹患者的血清 TGF-β1、IgE、IL-18 以及 T 细胞亚群 CD4+、CD8+、CD4+/CD8+水平，具有较好的临床疗效。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	章超
	张琳琳
	戴维维
	刘洪▲

关键词 ：转化生长因子-&beta, 1, 免疫球蛋白E, T 细胞亚群, 白介素18, 枸地氯雷他定, 慢性荨麻疹

Abstract： Objective To explore the effect of Desloratadine Citrate Disodium on chronic urticaria. Methods A total of 100 patients with chronic urticaria who were admitted to the Department of Dermatology of Jiujiang First People′s Hospital from January 2019 to January 2021 were selected as subjects and divided into the control group and the study group by the random number table method, with 50 patients in each group. The control group was treated with Loratadine Tablets, and the study group was treated with oral Desloratadine Citrate Disodium Tablets. Both groups were treated continuously for 28 days. The total score, pruritus score, wheal number, wheal size, total effective rate of different treatment courses and the levels of transforming growth factor-β1 (TGF-β1), immunoglobulin E (IgE), T cell subsets and interleukin-18 (IL-18) were compared between the two groups before treatment, 14 and 28 days after treatment. Results The pruritus scores, wheal number scores, wheal size scores and total scores of the two groups at 14 and 28 d after treatment were lower than those before treatment, with statistically significant differences (P<0.05). The pruritus score, wheal number score, wheal score and total score of the study group were all lower than those of the control group at 14 and 28 d after treatment, with statistically significant differences (P<0.05). In the two groups, the total effective rates at 28 d after treatment were higher than those at 14 d after treatment, with statistically significant differences (P<0.05). The total effective rates in the study group were higher than those in the control group at 14 and 28 d after treatment, with statistically significant differences (P<0.05). The TGF-β1, IgE, IL-18 and CD8+ in the two groups at 14 and 28 d after treatment were lower than those before treatment, with statistically significant differences (P<0.05). The TGF-β1, IgE IL-18 and CD8+in the study group were lower than those in the control group at 14 and 28 d after treatment, with statistically significant differences (P<0.05).The levels of CD4+ and CD4+/CD8+ in the two groups at 14 and 28 d after treatment were higher than those before treatment, with statistically significant differences (P<0.05).The levels of CD4+ and CD4+/CD8+ in the study group were higher than those in the control group at 14 and 28 d after treatment, with statistically significant differences (P<0.05). Conclusion Desloratadine Citrate Disodium can effectively regulate the levels of serum TGF-β1, IgE, IL-18 and T cell subsets of CD4+, CD8+, and CD4+/CD8+ in patients with chronic urticaria, showing good clinical efficacy.

Key words： Transforming growth factor-β1 Immunoglobulin E T cell subsets Interleukin-18 Desloratadine Citrate Disodium Chronic urticaria

基金资助:江西省卫生健康委科技计划项目（202140257）

引用本文:

章超;张琳琳;戴维维;刘洪▲. 枸地氯雷他定治疗慢性荨麻疹的效果[J]. 中国当代医药, 2021, 28(34): 162-166.
ZHANG Chao; ZHANG Lin-lin;DAI Wei-wei; LIU Hong▲. Effect of Desloratadine Citrate Disodium in the treatment of chronic urticaria. 中国当代医药, 2021, 28(34): 162-166.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I34/162

[1]	王振.枸地氯雷他定递减疗法治疗慢性荨麻疹的疗效观察及对血清总 IgE 水平的影响[J].临床研究，2019，27（12）：68-69.
[2]	孙杰.枸地氯雷他定片治疗慢性荨麻疹的效果及对血清总 IgE 水平的影响研究[J].皮肤病与性病，2020，182（3）：128-129.
[3]	谢枝刚.枸地氯雷他定治疗慢性荨麻疹的效果及用药安全性观察[J].医学理论与实践，2020，33（20）：91-92.
[4]	孙权.枸地氯雷他定治疗慢性荨麻疹疗效及对血清IgE水平的影响[J].皮肤病与性病，2019，41（5）：717-719.
[5]	徐延峰，杜威萍，骆志成，等.枸地氯雷他定治疗慢性荨麻疹的疗效及对血清白细胞介素 23 和 33、趋化因子PARC/CCL-18 的影响[J].中华皮肤科杂志，2019，52（5）：337-339.
[6]	王尧绍.皮肤病学[M].3 版.北京：人民卫生出版，1993：56.
[7]	国家中医药总局.中医病证诊断疗效标准[S].南京：南京大学出版社，1994：265.
[8]	黎舒敏，邱鸿琳，周俊琳.慢性荨麻疹患者发病影响因素与中医体质的相关性分析[J].中国初级卫生保健，2020，34（2）：84-86.
[9]	Kolkhir P，Pogorelov D，Darlenski R，et al.Management of chronic spontaneous urticaria：a worldwide perspective[J].World Allergy Organ J，2018，11（1）：14.
[10]	肖显俊，石云舟，张镭潇，等.慢性荨麻疹相关基因研究进展[J].中国皮肤性病学杂志，2020，34（1）：98-101.
[11]	何沅莉，单葵，曹雨微，等.慢性荨麻疹患者血清 IL-17、IL-23、TGF-β 水平检测分析[J].现代医药卫生，2018，34（3）：364-365，368.
[12]	吕纯鹏，康尔恂.慢性自身免疫性荨麻疹研究进展[J].国际皮肤性病学杂志，2016，42（4）：233-235.
[13]	杜威萍，徐延峰，张保恒.润肤止痒汤联合枸地氯雷他定治疗慢性荨麻疹的疗效观察及其对炎症因子和RANTES、MCP-1 的影响[J].中国中医药科技，2019，26（5）：651-654.
[14]	EL-Mezayen RE，Matsumoto T.In vitro responsiveness to IL-18 in combination with IL-12 or IL-2 by PBMC from patients with bronchial asthma and atopic dermatitis[J].Clin Immunol，2004，111（1）：61-68.
[15]	赵星云，张杰，黄海艳，等.联合用药治疗慢性自发性荨麻疹新进展[J].海南医学，2018，29（18）：2585-2587.